

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/445,105	03/07/2000	ZIVA MESSIKA	MESSIKA=2	9465	
75	590 09/16/2002				
BROWDY AND NEIMARK			EXAMINER		
624 9TH STRE SUITE 300			SEHARASEYON,	SEHARASEYON, JEGATHEESAN	
WASHINGTO	N, DC 20001		ART UNIT	PAPER NUMBER	
			1647		
			DATE MAILED: 09/16/2002	12	

Please find below and/or attached an Office communication concerning this application or proceeding.

• '			
	Application No.	Applicant(s)	
Advisory Action	9/445,105 MESSIKA ET AL.		
nancery near	Examiner	Art Unit	
	Jegatheesan Seharaseyon	1647	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	ress
THE REPLY FILED 8/15/02 FAILS TO PLACE THIS API Therefore, further action by the applicant is required to average in a section under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applica ) a timely filed amendment whicl	ation. A proper repl h places the applica	ation in
PERIOD FOR RE	EPLY [check either a) or b)]		
<ul> <li>a) The period for reply expires 4 months from the mailing date</li> <li>b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).</li> <li>Extensions of time may be obtained under 37 CFR 1.136(a). The</li> </ul>	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF	g date of the final rejecti HE FINAL REJECTION. R 1.136(a) and the appr	ion. See MPEP ropriate extension
fee have been filed is the date for purposes of determining the period of the under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officially filed, may reduce any earned patent term adjustment. See 37 Countries of the contract of the	the shortened statutory period for reply ce later than three months after the mai	originally set in the final	Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR	•		
2. The proposed amendment(s) will not be entered be	ecause:		
(a) \( \square\) they raise new issues that would require further	er consideration and/or search (	see NOTE below);	
(b) they raise the issue of new matter (see Note b	pelow);		
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or si	mplifying the
(d)  they present additional claims without canceli	ng a corresponding number of fi	inally rejected claim	S.
NOTE: See Continuation Sheet.			- 50
<ol> <li>Applicant's reply has overcome the following rejection</li> </ol>	ion(s):		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed	amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		dered but does NO	T place the
6. The affidavit or exhibit will NOT be considered bec raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were	e newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an
. The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: None.			
Claim(s) objected to:			
Claim(s) rejected: 1-12.			
Claim(s) withdrawn from consideration:			
8. $\square$ The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Exami	ner.
9.  Note the attached Information Disclosure Statemer	nt(s)( PTO-1449) Paper No(s)	<u></u> .	
10.  Other:			

U.S. Patent and Trademark Office PTO-303 (Rev. 04-01)

## Continuation She t (PTO-303)



Application No. 09/445,105

Continuation of 2. NOTE: Applicant has amended the claims now to read on substantially homogeneous glycosylated human TNF-alpha only, which changes the scope requiring a new search and consideration of the rejection.

JEFFREY STUCKER
PRIMARY EXAMINER